EBS:NYE-Emergent Biosolutions Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 9.35

Change

+0.41 (+4.59)%

Market Cap

N/A

Volume

1.64M

Analyst Target

USD 112.29
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

-0.96 (-0.50%)

USD 88.29B
HLN Haleon plc

-0.03 (-0.29%)

USD 48.57B
TAK Takeda Pharmaceutical Co Ltd A..

+0.19 (+1.33%)

USD 45.08B
RDY Dr. Reddy’s Laboratories Ltd..

-1.30 (-1.63%)

USD 13.46B
CTLT Catalent Inc

-0.12 (-0.20%)

USD 10.91B
ELAN Elanco Animal Health

+0.16 (+1.10%)

USD 7.26B
BHC Bausch Health Companies Inc

+0.05 (+0.60%)

USD 3.05B
AMRX Amneal Pharmaceuticals, Inc. C..

+0.10 (+1.17%)

USD 2.68B
CPHI China Pharma Holdings Inc

-0.01 (-3.86%)

USD 4.41M
YCBD cbdMD Inc

+0.01 (+2.61%)

USD 1.70M

ETFs Containing EBS

EBNK:CA Evolve European Banks Enh.. 5.01 % 0.00 %

+0.13 (+0.94%)

CAD 3.39M
IVES Amplify ETF Trust 3.60 % 0.00 %

+1.24 (+0.94%)

USD 0.02B
EMUM:SW iShares MSCI EMU Mid Cap .. 1.86 % 0.00 %

N/A

USD 0.13B
LGGE:XETRA L&G Quality Equity Divide.. 1.38 % 0.00 %

+0.11 (+0.94%)

USD 0.03B
LDEG:LSE L&G Quality Equity Divide.. 1.30 % 0.00 %

+6.60 (+0.94%)

N/A
IS3H:F iShares IV Public Limited.. 0.00 % 0.00 %

N/A

N/A
EL43:XETRA Deka MSCI Europe MC UCITS.. 0.00 % 0.00 %

+0.11 (+0.94%)

USD 0.02B
IS3H:XETRA iShares MSCI EMU Mid Cap .. 0.00 % 0.00 %

+0.48 (+0.94%)

USD 0.13B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 289.58% 100% F 100% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 289.58% 100% F 100% F
Trailing 12 Months  
Capital Gain 212.71% 100% F 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 212.71% 100% F 99% N/A
Trailing 5 Years  
Capital Gain -82.73% 20% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -82.73% 20% F 3% F
Average Annual (5 Year Horizon)  
Capital Gain -34.57% N/A N/A 1% F
Dividend Return -34.57% N/A N/A 1% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 55.61% N/A N/A 16% F
Risk Adjusted Return -62.15% N/A N/A 4% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector